A major publicly traded life science tools company has entered a technology assessment agreement with Phase Holographic Imaging (PHI). The purpose of the agreement is to assess PHI’s HoloMonitor technology for cell biology applications, primarily within immuno-oncology. The assessment is expected to extend over at least six months and to form the basis of the future relationship between the companies. PHI will provide instrumentation and technical support to facilitate the assessment.
With annual sales of several billion Swedish kronor, the company is a leading supplier of life science tools. Life science tools is the market segment within life science that provides life science companies, academia and hospitals with instruments, reagents, consumables and other laboratory related products.
Immuno-oncology aims to treat cancer by stimulating the patient’s immune system to attack the cancer. Due to recent clinical successes, immuno-oncology is rapidly gaining attention and was awarded the Nobel Prize in Physiology or Medicine 2018. Read more about the prize and immuno-oncology here.
Dendritic immune cells detect pathogens and activate the immune system’s T-cells to neutralize them. However, the immune system needs help to perceive cancer cells as pathogens. Most immuno-oncology therapies aim to treat cancer by activating the patient’s T cells to help the immune system neutralize cancer cells.
This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation.